Early clinical evidence suggests GLP-1 receptor agonists may improve psoriasis, hidradenitis suppurativa, and wound healing through anti-inflammatory and immunomodulatory effects, but larger trials are needed to confirm these dermatologic applications.
3 skin conditionsPsoriasis, hidradenitis suppurativa, and wound healing showing early improvements with GLP-1 receptor agonist peptide therapy
What the researchers found
Early clinical evidence from case reports, small cohorts, and short-duration trials suggests GLP-1 RAs may benefit several dermatologic conditions:
- Psoriasis: reductions in Psoriasis Area and Severity Index (PASI) scores
- Hidradenitis suppurativa (HS): improved disease activity and patient-reported symptoms
- Wound healing: fewer wound complications in retrospective datasets
These effects likely reflect both direct immunomodulation and indirect metabolic benefits (weight loss and reduced systemic inflammation). However, GLP-1 RAs can also cause dermatologic adverse events including pruritus (itching), drug eruptions, alopecia (hair loss), and acne, in addition to systemic side effects like gastrointestinal intolerance and biliary disease.
Why it matters
Millions of patients are now taking GLP-1 peptide drugs for diabetes and obesity. Dermatologists need to understand both the potential skin benefits and dermatologic side effects. If confirmed in larger trials, the anti-inflammatory properties of these peptides could offer an additional treatment avenue for chronic inflammatory skin diseases that are often challenging to manage — particularly in patients who already have metabolic comorbidities.
How the study worked
This is a continuing medical education (CME) review article published in JAAD (Journal of the American Academy of Dermatology), synthesizing available clinical evidence on GLP-1 receptor agonists in dermatologic applications. It covers case reports, small cohort studies, observational data, and short-duration trials, along with safety considerations.
What this study cannot tell us
The evidence base is very limited — mostly case reports, small cohorts, and short-duration studies. Most patients in existing reports had comorbid diabetes or obesity, making it impossible to separate the direct skin effects of GLP-1 RAs from the indirect benefits of weight loss and metabolic improvement. There is significant heterogeneity in the GLP-1 agents, dosing protocols, and skin conditions studied. No large randomized controlled trials have been completed for any dermatologic indication.
How to read the evidence
This is a CME review article summarizing early-stage clinical evidence (case reports, small cohorts, observational studies). The evidence for dermatologic applications is preliminary and insufficient for clinical recommendations without larger randomized trials.
When this study was published
Published in 2026 in JAAD, this review captures the very latest observations about GLP-1 RA effects on skin, making it among the first comprehensive dermatology-focused assessments of these peptide drugs.
The bigger picture
This review reflects a broader trend of discovering unexpected therapeutic applications for GLP-1 peptide drugs. Originally developed for blood sugar control, these drugs are now being studied for heart failure, kidney disease, fatty liver disease, neurodegeneration, and now dermatology. The anti-inflammatory and immunomodulatory properties of GLP-1 receptor activation appear to extend far beyond metabolic regulation, opening new frontiers for peptide-based therapeutics across multiple medical specialties.
Questions still open
- Do GLP-1 agonists directly modulate skin inflammation through GLP-1 receptors in the skin, or are the dermatologic benefits entirely secondary to metabolic improvements?
- Which specific GLP-1 agonist and dose would be most effective for psoriasis or hidradenitis suppurativa?
- How should dermatologists balance the potential skin benefits against dermatologic side effects like alopecia and drug eruptions?
Common questions
Can GLP-1 drugs like Ozempic help with skin conditions?
Should I tell my dermatologist if I'm taking a GLP-1 medication?
Read the original research
JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology.
Journal of the American Academy of Dermatology
Citation
Narla, Shanthi; Narla, Radhika R. (2026). JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.12.116